 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum PR Newswire WALTHAM, Mass., April...

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum

Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session Syndax Presents Positive Pediatric Data from...

Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass...

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

This is a Bullish indicator signaling SNDX's price could rise from here. Traders may explore going long the stock or buying call options...

Syndax Pharmaceuticals (SNDX, $23.76) Moving Average Convergence Divergence (MACD) Histogram turned positive on April 1, 2024

This is a signal that SNDX's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

Syndax Pharmaceuticals (SNDX, $23.76) Stochastic Oscillator left the overbought zone on April 01, 2024

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the ten ratings firms that are presently covering the firm, Marketbeat...

Brokerages Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Price Target at $34.42

Syndax Pharmaceuticals (NASDAQ:SNDX  Get Free Report)s stock had its buy rating reissued by stock analysts at HC Wainwright in a research report issued on Wednesday...

HC Wainwright Reiterates Buy Rating for Syndax Pharmaceuticals (NASDAQ:SNDX)

This indicator may be signaling SNDX's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Syndax Pharmaceuticals (SNDX, $23.77) entered Uptrend as Momentum indicator ascends above 0 level on Mar 28, 2024

Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia Syndax Announces Completion of Enrollment in...

Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Volume (M)	1.22M
52-Wk High	$25.34
52-Wk Low	$11.22

SNDX Syndax Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals